Dr. Sia Daneshmand - Extraperitoneal RPLND & MicroRNA 371

Episode 115

In this episode of It Takes Balls, Dr. Sia Daneshmand, a leading urologic oncologist at USC, joins the conversation to break down the realities of testicular cancer treatment, surgery, and long-term outcomes. Known for his expertise in complex cases and extraperitoneal RPLNDs, Dr. Daneshmand shares how advances in surgery and a personalized approach to care are improving survival while reducing unnecessary treatment.

The discussion dives into critical decisions patients face after diagnosis, including when surveillance vs. treatment is appropriate and how factors like tumor type, staging, and risk influence the path forward. Dr. Daneshmand explains the role of retroperitoneal lymph node dissection (RPLND), when it’s necessary, and how surgical expertise can dramatically impact outcomes and quality of life.

Beyond treatment, this episode explores the importance of being treated at high-volume centers, avoiding overtreatment, and understanding the long-term effects of both surgery and chemotherapy. Dr. Daneshmand also discusses the status and future of MicroRNA 371 biomarker testing.

Whether you’re newly diagnosed, considering surgery, or learning more about testicular cancer treatment options, this episode provides trusted insight from one of the leading experts in the field helping patients make informed decisions with confidence.

For more interviews with experts, visit this page.

Enjoy the podcast? Click Here to Show Your Support!

Click the links below to listen: